id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-321064-pe8466n1	Saraceni, Francesco	Severe COVID‐19 in a patient with chronic graft‐versus‐host disease after hematopoietic stem cell transplant successfully treated with ruxolitinib	2020-07-14		.txt	text/plain	1085	67	46	title: Severe COVID‐19 in a patient with chronic graft‐versus‐host disease after hematopoietic stem cell transplant successfully treated with ruxolitinib The selective JAK1/2 inhibitor ruxolitinib has shown promising results in the context of GVHD, and different trials are currently underway in patients with severe COVID‐19; nevertheless, no clinical observation of safety or efficacy of treatment with ruxolitinib in this context has been published yet. We describe a first case of severe COVID‐19 developed after hematopoietic stem cell transplantation in a patient with a concomitant chronic GVHD (cGVHD), in which a treatment with ruxolitinib was administered with good tolerance and positive outcome. Our report suggests that in this patient with severe COVID-19 developed after a hematopoietic stem cell transplant, treatment with ruxolitinib was feasible and well tolerated. Severe COVID-19 in a patient with chronic graft-versushost disease after hematopoietic stem cell transplant successfully treated with ruxolitinib	./cache/cord-321064-pe8466n1.txt	./txt/cord-321064-pe8466n1.txt